COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Фаза 2
Прекращено
NCT05000216
| Заболевание | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Pemphigus Vulgaris, Multiple Sclerosis |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|
| Статус | Прекращено |
|---|
| Участники | 258 участн. |
|---|
| Вмешательство | Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX) |
|---|
| Дата начала | 13.08.2021 |
|---|
| Дата завершения | 22.06.2023 |
|---|
| Публикация результатов | 22.08.2025 |
|---|
Кратко
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result \>200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 vaccine. The study will focus on 5 autoimmune diseases in adults: * Systemic Lupus Erythematosus (SLE) * Rheumatoid Arthritis (RA) * Multiple Sclerosis (MS) * Systemic Sclerosis (SSc), and * Pemphigus. This study will focus on 4 autoimmune diseases in pediatric participants: * Systemic Lupus Erythematosus (SLE) * Juvenile Idiopathic Arthritis (JIA) * Pediatric-Onset Multiple Sclerosis (POMS) * Juvenile Dermatomyositis (JDM)
Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A2: Pfizer-BioNTech + Continue IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A5: Pfizer-BioNTech + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A6: Janssen + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX) | NA Percentage of participants |
|---|
Percent of Stage 2 Adult Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort D, Arm D2: Alternative mRNA + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort D, Arm D4: Sanofi-GSK + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2: Alternative mRNA + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort E, Arm E4: Sanofi-GSK + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort F, Arm F2: Alternative mRNA + Withhold IS (BCDT) | NA Percentage of participants |
|---|
| Cohort F, Arm F3: Moderna mRNA-1273 + Withhold IS (BCDT) | NA Percentage of participants |
|---|
Percent of Stage 2 Pediatric Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX) | NA Percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.